- Extension study demonstrates favorable results in long term treatment of overactive bladder with vibegron, including improvements in incontinence efficacy, quality of life endpoints, and with good tolerability
- Long term EMPOWUR extension study data featured in an oral presentation at the virtual International Continence Society (ICS) Annual Meeting
- Meta-analysis on increased risk of incident dementia following the use of anticholinergics will also be presented at ICS
San Francisco, CA (UroToday.com) — Urovant Sciences announced positive efficacy and safety data from the vibegron EMPOWUR long term extension study with patient data over a total exposure of 52 weeks. The data demonstrate that vibegron improved quality of life (QoL) and incontinence efficacy endpoints with good long term tolerability in adult patients with overactive bladder (OAB) and symptoms of urge urinary incontinence (UUI), urgency, and urinary frequency.